An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Bladder Cancer: Diagnosis and Management.
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2015 Feb. (NICE Guideline, No. 2.)
Pancreatic cancer in adults: diagnosis and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2018 Feb. (NICE Guideline, No. 85.)
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Non-Hodgkin's Lymphoma: Diagnosis and Management.
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Haematological cancers: improving outcomes.
London: National Institute for Health and Care Excellence (NICE); 2016 May 25. (NICE Guideline, No. 47.)
Mecasermin (Increlex): CADTH Reimbursement Recommendation: Indication: For the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2011 Apr. (NICE Clinical Guidelines, No. 122.)
Addendum to Haematological Cancers: improving outcomes (update).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Cabozantinib (Cabometyx): CADTH Reimbursement Recommendation: Indication: Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic renal cell carcinoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Trifluridine-Tipiracil (Lonsurf): CADTH Reimbursement Recommendation: Indication: In combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have previously been treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Colorectal cancer.
London: National Institute for Health and Care Excellence (NICE); 2021 Dec 15. (NICE Guideline, No. 151.)
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines.
Bethesda (MD): American College of Medical Genetics; 1999.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Thyroid cancer: assessment and management.
London: National Institute for Health and Care Excellence (NICE); 2022 Dec 19. (NICE Guideline, No. 230.)
CADTH Canadian Drug Expert Committee Recommendation: Tapentadol Hydrochloride (Nucynta Extended-Release — Paladin Labs Inc.): Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.
CADTH Canadian Drug Expert Committee Recommendation: Cladribine (Mavenclad — EMD Serono): Indication: Relapsing-Remitting Multiple Sclerosis [Internet].
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on